domesticsale.info - Pobierz Google Chrome instalki, download

BUY NOW For Sale 70%!
buy viagra

Topical calcineurin inhibitors black box warning cipro

  • World Gastroenterology Organisation (WGO). World Gastroenterology Organisation Global Guideline. Inflammatory bowel disease: a global perspective. Munich, Germany: World Gastroenterology Organisation (WGO); 2009.

  • warning
  • American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology. 2003 Nov. 125(5):1503-7. [Medline].

  • Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010 Mar. 105(3):501-23; quiz 524. [Medline].

  • Kiran RP, Nisar PJ, Church JM, Fazio VW. The role of primary surgical procedure in maintaining intestinal continuity for patients with Crohn's colitis. Ann Surg. 2011 Jun. 253(6):1130-5. [Medline].

  • Agrawal D, Rukkannagari S, Kethu S. Pathogenesis and clinical approach to topical calcineurin inhibitors black box warning cipro extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol Dietol. 2007 Sep. 53(3):233-48. [Medline].

  • Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am. 2007 Jun. 87(3):575-85. [Medline].

  • Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007 May. 39(5):596-604. [Medline]. [Full Text].

  • Tsianos EV, Katsanos KH, Tsianos VE. Role of genetics in the diagnosis and prognosis of Crohn's disease. World J Gastroenterol. 2012 Jan 14. 18(2):105-18. [Medline]. [Full Text].

  • Lashner B. Inflammatory bowel disease. Carey WD, ed. Cleveland Clinic: Current Clinical Medicine -- 2009. Philadelphia, Pa: Saunders; 2009.

  • Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn's disease. Am Fam Physician. 2011 Dec 15. 84(12):1365-75. [Medline].

  • Trinchieri A, Lizzano R, Castelnuovo C, Zanetti G, Pisani E. Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease. Arch Ital Urol Androl. 2002 Jun. 74(2):61-4. [Medline].

  • Amre DK, D'Souza S, Morgan K, Seidman G, Lambrette P, Grimard G, et al. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am J Gastroenterol. 2007 Sep. 102(9):2016-25. [Medline].

  • Jantchou P, Morois S, Clavel-Chapelon F, Boutron-Ruault MC, Carbonnel F. Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study. Am J Gastroenterol. 2010 Oct. 105(10):2195-201. [Medline].

  • Bengtson MB, Solberg IC, Aamodt G, Jahnsen J, Moum B, Vatn MH. Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring. Inflamm Bowel Dis. 2010 May. 16(5):847-55. [Medline].

  • Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am. 2007 Jun. 87(3):575-85. [Medline].

  • Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002 May 11. 359(9318):1661-5. [Medline].

  • Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001 May 31. 411(6837):599-603. [Medline].

  • Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006 Dec 1. 314(5804):1461-3. [Medline].

  • Glas J, Seiderer J, Wetzke M, Konrad A, Török HP, Schmechel S, et al. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One. 2007 Sep 5. 2(9):e819. [Medline]. [Full Text].

  • Van Limbergen J, Russell RK, Nimmo ER, Drummond HE, Smith L, Davies G, et al. IL23R Arg381Gln is associated with childhood onset inflammatory bowel disease in Scotland. Gut. 2007 Aug. 56(8):1173-4. [Medline]. [Full Text].

  • Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008 Aug. 40(8):955-62. [Medline]. [Full Text].

  • Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007 Feb. 39(2):207-11. [Medline].

  • Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007 Jul. 39(7):830-2. [Medline]. [Full Text].

  • Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, Franchimont D, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 2007 Apr 20. 3(4):e58. [Medline]. [Full Text].

  • Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc. 2007 Aug. 66(3):307-15. [Medline].

  • Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007 Jun 7. 447(7145):661-78. [Medline]. [Full Text].

  • Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet. 2008 Jun. 40(6):710-2. [Medline]. [Full Text].

  • Weersma RK, Zhernakova A, Nolte IM, Lefebvre C, Rioux JD, Mulder F, et al. ATG16L1 and IL23R are associated with inflammatory bowel diseases but not with celiac disease in the Netherlands. Am J Gastroenterol. 2008 Mar. 103(3):621-7. [Medline].

  • Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009 Feb. 41(2):216-20. [Medline]. [Full Text].

  • Okada Y, Yamazaki K, Umeno J, Takahashi A, Kumasaka N, Ashikawa K, et al. HLA-Cw1202-B5201-DRB11502 haplotype increases risk for ulcerative colitis but reduces risk for Crohn's disease. Gastroenterology. 2011 Sep. 141(3):864-871.e1-5. [Medline].

  • Centers for Disease Control and Prevention. Inflammatory bowel disease (IBD). Available at http://www.cdc.gov/ibd/#epidIBD. Accessed: August 6, 2012.

  • Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan. 142(1):46-54.e42; quiz e30. [Medline].

  • Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004 May. 126(6):1504-17. [Medline].

  • Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000 Mar. 46(3):336-43. [Medline]. [Full Text].

  • Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998 Jun. 114(6):1161-8. [Medline].

  • Roth MP, Petersen GM, McElree C, Feldman E, Rotter JI. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology. 1989 Oct. 97(4):900-4. [Medline].

  • Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology. 1991 Jan. 100(1):143-9. [Medline].

  • Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996 Nov. 39(5):690-7. [Medline]. [Full Text].

  • Langholz E. Current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol. 2010 Mar. 3(2):77-86. [Medline]. [Full Text].

  • Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 2003 Dec. 125(6):1583-90. [Medline].

  • Jess T, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ 3rd, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006 Sep. 55(9):1248-54. [Medline]. [Full Text].

  • Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology. 2007 Dec. 133(6):1779-86. [Medline].

  • Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007 Mar. 102(3):662-7. [Medline].

  • [Guideline] Farraye FA, Odze RD, Eaden J, Itzkowitz SH, McCabe RP, Dassopoulos T, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010 Feb. 138(2):738-45. [Medline].

  • AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. 2010. Available at http://www.gastrojournal.org/article/S0016-5085(09)02202-1/fulltext. Accessed: August 6, 2012.

  • Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas. London, UK: National Institute for Health and Clinical Excellence (NICE); 2011. Available at http://guideline.gov/content.aspx?id=34830. Accessed: August 6, 2012.

  • Barclay L. COPD, Asthma May Up Risk for Inflammatory Bowel Disease. Medscape Medical News. Available at http://www.medscape.com/viewarticle/835213. Accessed: November 22, 2014.

  • Brassard P, Vutcovici M, Ernst P, Patenaude V, Sewitch M, Suissa S, et al. Increased incidence of inflammatory bowel disease in Québec residents with airway diseases. Eur Respir J. 2014 Nov 18. [Medline].

  • Brooks AJ, Rowse G, Ryder A, Peach EJ, Corfe BM, Lobo AJ. Systematic review: psychological morbidity in young people with inflammatory bowel disease - risk factors and impacts. Aliment Pharmacol Ther. 2016 Jul. 44 (1):3-15. [Medline].

  • Meucci G, Vecchi M, Astegiano M, Beretta L, Cesari P, Dizioli P, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000 Feb. 95(2):469-73. [Medline].

  • Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold Ø, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006 Jul. 12(7):543-50. [Medline].

  • Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007 Dec. 5(12):1430-8. [Medline].

  • Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb. 104(2):465-83; quiz 464, 484. [Medline].

  • Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther. 2012 Mar. 35(6):625-33. [Medline].

  • Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med. 2010 Mar. 42(2):97-114. [Medline].

  • Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011. 106:110-119.

  • [Guideline] Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010 Jan. 16(1):112-24. [Medline].

  • Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009 Jan. 41(1):56-66. [Medline].

  • Reuters Health. Study backs wider use of fecal calprotectin in pediatric IBD workup. Medscape Medical News. May 27, 2013. [Full Text].

  • Henderson P, Anderson NH, Wilson DC. The Diagnostic Accuracy of Fecal Calprotectin During the Investigation of Suspected Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2013 May 14. [Medline].

  • Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012 Jul. 18(7):1340-55. [Medline].

  • D'Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007 Apr. 22(4):429-37. [Medline].

  • Panés J, Bouzas R, Chaparro M, García-Sánchez V, Gisbert JP, Martínez de Guereñu B, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther. 2011 Jul. 34(2):125-45. [Medline].

  • Rimola J, Ordás I, Rodriguez S, García-Bosch O, Aceituno M, Llach J, et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011 Aug. 17(8):1759-68. [Medline].

  • Paulsen SR, Huprich JE, Fletcher JG, Booya F, Young BM, Fidler JL, et al. CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. Radiographics. 2006 May-Jun. 26(3):641-57; discussion 657-62. [Medline].

  • Guimarães LS, Fidler JL, Fletcher JG, Bruining DH, Huprich JE, Siddiki H, et al. Assessment of appropriateness of indications for CT enterography in younger patients. Inflamm Bowel Dis. 2010 Feb. 16(2):226-32. [Medline].

  • Solem CA, Loftus EV Jr, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008 Aug. 68(2):255-66. [Medline].

  • Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn's disease. Am Fam Physician. 2011 Dec 15. 84(12):1365-75. [Medline].

  • Baumgart DC. Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when?. Dig Dis. 2011. 29 Suppl 1:32-5. [Medline].

  • Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006 Apr. 63(4):558-65. [Medline]. [Full Text].

  • Li CY, Zhang BL, Chen CX, Li YM. OMOM capsule endoscopy in diagnosis of small bowel disease. J Zhejiang Univ Sci B. 2008 Nov. 9(11):857-62. [Medline]. [Full Text].

  • Yamamoto H, Kita H, Sunada K, Hayashi Y, Sato H, Yano T, et al. Clinical outcomes of double-balloon endoscopy for the diagnosis and treatment of small-intestinal diseases. Clin Gastroenterol Hepatol. 2004 Nov. 2(11):1010-6. [Medline].

  • Möschler O, May A, Müller MK, Ell C. Complications in and performance of double-balloon enteroscopy (DBE): results from a large prospective DBE database in Germany. Endoscopy. 2011 Jun. 43(6):484-9. [Medline].

  • Gross SA, Stark ME. Initial experience with double-balloon enteroscopy at a U.S. center. Gastrointest Endosc. 2008 May. 67(6):890-7. [Medline].

  • Gerson LB, Flodin JT, Miyabayashi K. Balloon-assisted enteroscopy: technology and troubleshooting. Gastrointest Endosc. 2008 Dec. 68(6):1158-67. [Medline].

  • Amezaga AJ, Van Assche G. Practical approaches to "top-down" therapies for Crohn's disease. Curr Gastroenterol Rep. 2016 Jul. 18 (7):35. [Medline].

  • Frøslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007 Aug. 133(2):412-22. [Medline].

  • Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009 Sep. 15(9):1295-301. [Medline].

  • Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010 Feb. 138(2):463-8; quiz e10-1. [Medline].

  • Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15. 362(15):1383-95. [Medline].

  • Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand?. Curr Gastroenterol Rep. 2010 Dec. 12(6):471-8. [Medline].

  • Feagan BG, Lémann M, Befrits R, Connell W, D'Haens G, Ghosh S, et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis. 2012 Jan. 18(1):152-60. [Medline].

  • Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb. 17(1):131-7. [Medline].

  • Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):590-9; quiz 600. [Medline].

  • Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011 Jun. 9(6):483-489.e3. [Medline].

  • Gordon M, Naidoo K, Thomas AG, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2011. (1):CD008414. [Medline].

  • Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec. 137(6):1934-43.e1-3. [Medline].

  • Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010 Oct. 105(10):2218-27. [Medline].

  • Mach T. Clinical usefulness of probiotics in inflammatory bowel diseases. J Physiol Pharmacol. 2006 Nov. 57 Suppl 9:23-33. [Medline].

  • Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):661-73. [Medline].

  • [Guideline] Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar. 130(3):935-9. [Medline]. [Full Text].

  • Silverman J, Otley A. Budesonide in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2011 Jul. 7(4):419-28. [Medline].

  • Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996 May. 110(5):1416-21. [Medline].

  • Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):630-42. [Medline].

  • Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015 Jun. 148 (7):1320-9.e3. [Medline].

  • Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):644-59, quiz 660. [Medline].

  • Rubin DT, Panaccione R, Chao J, Robinson AM. A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin. 2011 Sep. 27(9):1803-13. [Medline].

  • Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012 Jan. 142(1):63-70.e5; quiz e31. [Medline].

  • Rubin DT, Panaccione R, Chao J, Robinson AM. A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin. 2011 Sep. 27(9):1803-13. [Medline].

  • US Food and Drug Administration. FDA drug safety communication: new risk factor for progressive multifocal leukoencephalopathy (PML) associated with Tysabri (natalizumab). Available at http://www.fda.gov/drugs/drugsafety/ucm288186.htm. Accessed: July 11, 2012.

  • Brown T. FDA OKs Vedolizumab (Entyvio) for Ulcerative Colitis, Crohn’s. Medscape Medical News. May 20 2014. [Full Text].

  • Chen JH, Andrews JM, Kariyawasam V, et al, for the IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther. 2016 Jul. 44 (2):127-44. [Medline].

  • Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol. 2010 Jun. 56(2):233-43. [Medline].

  • US Food and Drug Administration. Tumor Necrosis Factor-alpha (TNFα) Blockers: Label Change - Boxed Warning Updated for Risk of Infection from Legionella and Listeria Posted September 7, 2011. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm270977.htm. Accessed: April 5, 2012.

  • Mokrowiecka A, Daniel P, Slomka M, Majak P, Malecka-Panas E. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology. 2009 Jan-Feb. 56(89):162-6. [Medline].

  • Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?. Eur J Clin Pharmacol. 2009 Oct. 65(10):963-70. [Medline].

  • de Silva S, Ma C, Proulx MC, et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2011 Nov. 9(11):972-80. [Medline].

  • Lazarev M, Ullman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis. 2010 May. 16(5):830-5. [Medline].

  • Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. Sexual and reproductive health for individuals with inflammatory bowel disease. London (UK): Faculty of Sexual and Reproductive Healthcare (FSRH); 2009.

  • Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn's disease. J Gastroenterol. 2010. 45(1):24-9. [Medline].

  • Helwick C. Low vitamin D exacerbates inflammatory bowel disease. Medscape Medical News. May 21, 2013. [Full Text].

  • Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of vitamin D status is associated with reduced risk of surgery and hospitalization in inflammatory bowel disease: a prospective study. Gastroenterology. 2013 May. 144(5 Suppl 1):S-1.

  • Raftery TC, Healy M, Cox G, et al. Vitamin D supplementation improves muscle strength, fatigue and quality of life in patients with Crohn's disease in remission: results of a randomized double-blind placebo-controlled study. Gastroenterology. 2013 May. 144(5 Suppl 1):S-227.

  • Johannesson E, Simren M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011 May. 106(5):915-22. [Medline].

  • Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010 May. 16(5):881-95. [Medline].

  • Pew Research Center. The Databank: 10,000 - Baby Boomers retire. Available at http://pewresearch.org/databank/dailynumber/?NumberID=1150. Accessed: August 3, 2012.

  • Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011 Sep. 17(9):1846-54. [Medline].

  • Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011 May. 33(9):1053-8. [Medline].

  • Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford). 2007 Apr. 46(4):695-8. [Medline].

  • O'Donnell S, O'Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther. 2008 May. 27(10):885-94. [Medline].

  • Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, et al. Safety of thiopurines and anti-TNF-a drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013 Mar. 108(3):433-40. [Medline].

  • Rajaratnam SG, Eglinton TW, Hider P, Fearnhead NS. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. Int J Colorectal Dis. 2011 Nov. 26(11):1365-74. [Medline].

  • Bartels SA, D'hoore A, Cuesta MA, Bensdorp AJ, Lucas C, Bemelman WA. Significantly Increased Pregnancy Rates After Laparoscopic Restorative Proctocolectomy: A Cross-Sectional Study. Ann Surg. 2012 May 17. [Medline].

  • Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006 Apr. 55(4):505-9. [Medline]. [Full Text].

  • Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012 Mar 20. [Medline].

  • Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003 Jan. 124(1):9-17. [Medline].

  • García-Erce JA, Gomollón F, Muñoz M. Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases. World J Gastroenterol. 2009 Oct 7. 15(37):4686-94. [Medline]. [Full Text].

  • Granlund AB, Beisvag V, Torp SH, Flatberg A, Kleveland PM, Ostvik AE, et al. Activation of REG family proteins in colitis. Scand J Gastroenterol. 2011 Nov. 46(11):1316-23. [Medline]. [Full Text].

  • Kennedy NA, Rhatigan E, Arnott ID, et al. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther. Nov 2013. 38(10):1255-66. [Medline].

  • Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Lamberts M, Khalid U, et al. Prognosis After First-Time Myocardial Infarction in Patients With Inflammatory Bowel Disease According to Disease Activity: Nationwide Cohort Study. Circ Cardiovasc Qual Outcomes. 2014 Oct 14. [Medline].

  • Stiles S. Heartwire. Ulcerative colitis, Crohn’s flares may raise post-MI risk: registry study. Medscape Medical News. October 17, 2014. [Full Text].

  • {Guideline} National Institute for Health and Clinical Excellence (NICE). Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas. London, UK: National Institute for Health and Clinical Excellence (NICE); 2011.

  • Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015 Jan. 50 (1):90-112. [Medline].

  • Garg SK, Loftus EV Jr. Risk of cancer in inflammatory bowel disease: going up, going down, or still the same?. Curr Opin Gastroenterol. 2016 Jul. 32 (4):274-81. [Medline].

  • Schaefer JS. MicroRNAs: how many in inflammatory bowel disease?. Curr Opin Gastroenterol. 2016 Jul. 32 (4):258-66. [Medline].

  • Bernstein CN. Does everyone with inflammatory bowel disease need to be treated with combination therapy?. Curr Opin Gastroenterol. 2016 Jul. 32 (4):287-93. [Medline].

  • Atreya R, Neurath MF. From bench to bedside: molecular imaging in inflammatory bowel diseases. Curr Opin Gastroenterol. 2016 Jul. 32 (4):245-50. [Medline].


Source: http://emedicine.medscape.com/article/179037-treatment


BUY NOW For Sale 70%!
buy viagra

Amoxicillin Purchase Online - Guaranteed anonymity Bombastus glaubersalz dosierung ciprofloxacin

Topical calcineurin inhibitors black box warning cipro CCCI Cyprus Chamber of Comerce and Industry
Topical calcineurin inhibitors black box warning cipro Cached
Topical calcineurin inhibitors black box warning cipro Cipro (Ciprofloxacin Side Effects, Interactions, Warning)
Topical calcineurin inhibitors black box warning cipro Cipro (Ciprofloxacin) Patient Information: Side Effects and
Topical calcineurin inhibitors black box warning cipro Cipro XR (Ciprofloxacin Extended-Release Side Effects)
Topical calcineurin inhibitors black box warning cipro Ciprofloxacin
Topical calcineurin inhibitors black box warning cipro Ciprofloxacin (Cipro) - Side Effects, Dosage, Interactions
Topical calcineurin inhibitors black box warning cipro Ciprofloxacin (Mixture) Oral : Uses, Side Effects
Ciprofloxacin 2 mg/ml Solution for Infusion - Summary of DailyMed - CIPROFLOXACIN - ciprofloxacin tablet I verbi in spagnolo - m Medikamente: Alle Wirkstoffe von A-Z Nebenwirkung - Wodia Pharmazeutische Zeitung online: Sepsis: Gef hrliches Tizanidine: MedlinePlus Drug Information
BUY NOW For Sale 70%!
buy viagra